Evogene
EVGN
22 hedge funds and large institutions have $39.3M invested in Evogene in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
22% more funds holding
Funds holding: 18 → 22 (+4)
0.03% more ownership
Funds ownership: 2.99% → 3.02% (+0.03%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
22% less capital invested
Capital invested by funds: $50.1M → $39.3M (-$10.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$765K |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$572K |
| 3 |
MCM
Moon Capital Management
New York
|
+$323K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$211K |
| 5 |
Jane Street
New York
|
+$168K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$936K |
| 2 |
Goldman Sachs
New York
|
-$577K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$489K |
| 4 |
Citigroup
New York
|
-$18.2K |
| 5 |
SWM
Stockman Wealth Management
Billings,
Montana
|
-$3.72K |
EVGN Hedge Fund Activity: Q4 2016 in Review
22 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2016, worth a combined $39.3M — down 22% from $50.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVGN positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was UBS Group, adding an estimated $765K. The largest seller was Waddell & Reed Financial, cutting an estimated $936K.
- 22 institutional investors held Evogene (EVGN) as of Q4 2016, up from 18 in Q3 2016.
- Funds reported $39.3M of Evogene stock for Q4 2016, down 22% quarter-over-quarter.
- 5 funds opened new Evogene positions in Q4 2016 and 1 closed out, a net change of +4 holders.
- The largest Evogene buyer in Q4 2016 was UBS Group, an estimated $765K added.
- The largest Evogene seller in Q4 2016 was Waddell & Reed Financial, an estimated $936K sold.
Based on aggregated 13F filings for Q4 2016.